Coronally Advanced Flap with a Xenogeneic Collagen Matrix or an rhPDGF-BB Regenerative Approach for Bilateral...

This split-mouth trial investigated the efficacy of treating bilateral gingival recessions with either a xenogeneic cross-linked collagen matrix (CCM) or recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with a bone allograft (AG). Ten patients were treated with a coronally advanced flap, either with CCM or rhPDGF-BB + AG. The primary outcome was percentage of mean root coverage (mRC) at 12 months. Additional outcomes included clinical and volumetric measurements; patient-reported outcome measures (PROMs) for pain, swelling, and esthetics; and ultrasonographic assessment of gingival thickness (GT) and position of the buccal bone. At 12 months, both groups showed significant improvements, with an mRC of 78.6% in the CCM group and 82.3% in the rhPDGF-BB + AG group. A 3D analysis of both groups showed comparable volumetric gain. CCM-treated sites displayed higher ultrasonographic echogenicity in GT (P < .01) than rhPDGF-BB + AG sites. The rhPDGF-BB + AG group showed greater reductions in the buccal bone dehiscence (mean: 2.03 mm; P < .01), less swelling during the first 3 days, and slightly greater mRC. CCM and rhPDGF-BB + AG were effective in treating multiple adjacent gingival recessions. CCM promotes greater gains in gingival thickness, while rhPDGF-BB + AG resulted in significantly less buccal bone dehiscenace.